RISE Test Facilities for the Measurement of Ultra-Low Flow Rates and Volumes with a Focus on Medical Applications
2022 (English)In: Applied Sciences, E-ISSN 2076-3417, Vol. 12, no 16, article id 8332Article in journal (Refereed) Published
Abstract [en]
In the framework of the ongoing EMPIR JRP 18HLT08 Metrology for Drug Delivery (MeDDII), a main task is to improve dosing accuracy and enable traceable measurements of volume, flow and pressure of existing drug delivery devices and in-line sensors operating, in some cases, at ultra-low flow rates. This can be achieved by developing new calibration methods and by expanding existing metrological infrastructure. The MeDDII project includes, among other issues, investigations on fast changing flow rates, physical properties of liquid mixtures and occlusion phenomena to avoid inaccurate measurement results and thus improve patient safety. This paper describes the extension of an existing measurement facility at RISE and the design and construction of a new measurement facility to be able to carry out such investigations. The new measurement facility, which is based on the dynamic gravimetric method, is unique worldwide in respect of the lowest measurable flow rate. The gravimetric measuring principle is pushed to the limits of what is feasible. Here, the smallest changes in the ambient conditions have a large influence on the measurement accuracy. The new infrastructure can be used to develop and validate novel calibration procedures for existing drug delivery devices over a wide flow rate range. The extension of the measurement facilities also enables inline measurement of the pressure and the dynamic viscosity of Newtonian liquids. For this purpose, it is ensured that all measurements are traceable to primary standards. © 2022 by the authors.
Place, publisher, year, edition, pages
MDPI , 2022. Vol. 12, no 16, article id 8332
Keywords [en]
drug delivery, flow measurement, IDA, insulin pump, microflow, nanoflow, syringe pump
National Category
Mathematics
Identifiers
URN: urn:nbn:se:ri:diva-60290DOI: 10.3390/app12168332Scopus ID: 2-s2.0-85137987406OAI: oai:DiVA.org:ri-60290DiVA, id: diva2:1702355
Note
Funding details: Horizon 2020 Framework Programme, H2020; Funding details: European Association of National Metrology Institutes, EURAMET; Funding details: European Metrology Programme for Innovation and Research, EMPIR; Funding details: VINNOVA, 2014-05078; Funding text 1: The authors greatly acknowledge the financial support of Vinnova (Sweden’s Innovation Agency) project 2014-05078 as a basis for this work. This work was supported by the European Association of National Metrology Institutes (EURAMET) through the European Metrology Programme for Innovation and Research (EMPIR) Joint Research Project (JRP) 18HLT08 Metrology for Drug Delivery (MeDDII). The EMPIR initiative is co-funded by the European Union’s Horizon 2020 research and innovation programme and the EMPIR Participating States.
2022-10-102022-10-102024-04-17Bibliographically approved